CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Decrease in Short Interest

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) saw a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 4,800 shares, a decrease of 25.0% from the February 13th total of 6,400 shares. Based on an average daily volume of 8,600 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research report on Friday, November 29th. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of CollPlant Biotechnologies in a report on Wednesday, February 12th.

Institutional Trading of CollPlant Biotechnologies

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in CollPlant Biotechnologies during the 4th quarter worth $38,000. Wells Fargo & Company MN grew its position in shares of CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after buying an additional 4,405 shares in the last quarter. AMH Equity Ltd increased its stake in shares of CollPlant Biotechnologies by 17.4% during the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after buying an additional 17,295 shares during the period. Finally, Benjamin Edwards Inc. bought a new stake in shares of CollPlant Biotechnologies in the third quarter valued at about $112,000. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Price Performance

Shares of CLGN opened at $3.30 on Tuesday. The firm has a market capitalization of $37.76 million, a price-to-earnings ratio of -2.14 and a beta of 1.07. The company has a 50-day moving average of $3.66 and a 200 day moving average of $4.06. CollPlant Biotechnologies has a 1-year low of $3.00 and a 1-year high of $6.75.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.